Really "flagrant factual violations"? Some of the contents I post are facts and others are my predications. You really do not see the benefit of this drug, come to your own opinion on any investment and think outside the box (you have a problem if this caused an issue). I will educate you on what I expect from this company. Per the CC: 1. Majority of the operations relate to Medicare/Medicaid (around 4mil total operation for 2015). 2. The drug used by physician is a compound. 3. Physicians cannot use compounds if there is an approved drug (kind of kills the peak sale predication of 488mil at a sales price of 465). 4. EU approval this year. 5. EU sales in the second Q or half I forgot what was said. 6. Started making calls to physician during August. 7. Advertisement in publication. 8. Peer review publication. 9. They will target the physicians that perform many of these operations. My experience: 1. Compound is used when there is no FDA approved drug or the FDA approved drugs will not benefit the patient. 2. I do not see the majority of physicians not using this the FDA approved product. If a physician was to use a compound they better justify why it is a better to use a compound (compound drugs are not FDA approved). 3. Even if a physician was to use compounds on some patients they still need to use the FDA approved drug, if a physician was to use a compound on all patients, what would be the defense if the patient files were pulled for review? It is proved the FDA approved drug is better. 4. Why would a physician spend time with compounds when there is an FDA approved drug? 5. I expect the phase III test centers to start using the product. With the early start in getting the word out sales should be strong.
I might of missed a couple of points. As for peak sales of 488mil for the only FDA approved drug for around 4 mil operation at 465 is low, unless majority of the physician can justify using compounds. I think most will use it
I told you, tiny comes out bashing, it's time to buy. This guy is 5 for 5 over the past year as a contrarian indicator. You would be up over 200% simply by doing the opposite of what he has said.
Plus there is a nice increase in the procedures based on projections. Not to mention world wide procedures will be around 20mil. Not sure what the sales price will be but it will just add to the sales figure.
Prior to the Medicare reimbursement, the analysts reports (still out there) were based on sale price of 200-250 or 200-300 with peak sales of 500-700 mil. The selling price at 465 allows for greater profit (some to be eaten up by the extra sales force). After 2-3 years, if this was not paid on pass thru, it would be included in the bundle (the non wage portion would be increased, and the drug would be reimbursed. It would be up to OMER to match the reimbursement if there was a drop, which I think they would to keep the physicians happy).
are you going to keep posting this nonsense, and follow this all the way up to $40pps ? i am buying more right now, ty
InfinityStockPicks has been sending out some legit messages the past fee days. If you guys haven't looked into them you really should. Made an easy 2600 on this trade. I can't believe their alerts. Google them.
now talking 400-500. that's double and could mean nearly double rev from product. original rev projections were 300-600M, now likely 600-1.2B
inVentiv's initial 20 dedicated Omidria sales reps have been knocking on ophthalmologist and surgical center doors since August.
Just two months later, in October 2014, they entered into an amendment to the agreement with inVentiv for twenty additional sales reps in the USA, doubling the sales force. It seems very likely that the negotiations for this amendment occurred before the October 29th pass-through reimbursement notification.
IMO, this indicates the Omidria rollout is going extremely well. While not wanting to be, or sound, overconfident, Greg Demopulos said on the CC, "we frankly could not have scripted a better scenario than the one into which we are launching".
Also IMO, the folks with the six million short OMER shares have to be very uneasy. They may look in the mirror soon and think $18+ would have been a smart place to cover.
my guess is it will sit around the pps 22-23, until we hear of EU approval, and the launch in jan2015. after that, i can easily see this over 30 by qtr1 2015. thats not even considering if we get good trial results on their other pipeline candidates. glta
Sentiment: Strong Buy
If you had been lucky enough to be following this stock from the lows in April 2013 and instead buying the stock and holding on you just watched it day after day and didn't buy because you have some worthless model that said you should not buy it if it rises above $7. Instead you just watch it as it moves higher and higher and the model you bought from some Wade Cook type tells you not to buy.
I can understand why you would be VERY bitter and angry. Unfortunately instead of leraning from your mistakes you take a hardline and continue to follow a model that has proven worthless. And then to boot, you come on the thechat board and act like a small child instead of admitting your mistakes
On their website and in yesterday's 10-Q, OMER said, ""OMS103, a PharmacoSurgery product candidate, is being developed for use during arthroscopic procedures, including partial meniscectomy surgery. Our Phase 3 clinical program in arthroscopic partial meniscectomy surgery may be redesigned to include reduction of early postoperative pain as the primary endpoint. In addition, we are evaluating alternative approaches for making OMS103 commercially available, such as through a registered outsourcing facility without the need to conduct any additional clinical trials."
Apparently OMS103, a blend of FDA-approved constituents, is being considered as a marketing candidate without the need for ANY additional trials or FDA approvals.
Think about it ...... Reducing inflammation and post-op pain at surgical sites sure sounds like quite a good thing.
And not just in knees!